Nanomedicines and Drug Delivery Systems Group, iMed.UL – Research Institute for Medicines and Pharmaceutical Sciences, Faculdade de Farmácia, Universidade de Lisboa (FFUL), Lisboa, Portugal
Keywords of expertise: 1. Nanomedicines, 2. Pulmonary Administration, 3. Oncology, 4. Cell Biology; Toxicology
Golden Paragraph: Assessment of in-vivo/in-vitro response to pulmonary and lymphatic absorption and clearance of the pharmaceutical nanoparticulate dispersed dosage forms. Biodistribution studies using nuclear medicine approaches.
Nanotechnology and intracellular Target: Design of innovative platforms for drug and gene delivery (e.g., Lipid nanoparticles, polymeric micelles and lipopolyplexes) using “smart” biomaterials.
Receptor-ligand strategies in order to develop patentable nanoscale delivery systems for selective cell targeting (e.g. Cd44+ in cancer stem cells) using molecular biology tools and adequate cell models.
Nanotechnology: Oncological pharmaceutical dosage forms development and full characterization of the designed systems. Assessment of properties of the nanoscale developed colloids, focusing in the relation between processes and materials. Applications of the lipid-based carriers for the intracellular deliver of new RNAi strategies against metastatic cancer sub-populations (signalling cascades, intracellular pathways and transcriptional proteins).
Interaction between nanoparticles and cellular targets: Intracellular nanoparticles trafficking, in vitro efficacy and toxicity and in vitro/in vivo nanoparticulate system efficacy. Evaluation of pulmonary or mucosal nanoparticles administration and further implications on the their lymphatic uptake.
Ethical implications of health-related innovations and experimentation.